1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 50
Sponsor: NCI, Other
Protocol IDs: EURO-EWING-INTERGROUP-EE99, EBMT-INTERGROUP-EE99, EORTC-62981, GPOH-AUSTRIA-INTERGROUP-EE99, GPOH-GERMANY-INTERGROUP-EE99, SFOP-INTERGROUP-EE99, SWS-SAKK-INTERGROUP-EE99, CCLG-INTERGROUP-EE99, COG-AEWS0331, NCT00020566, AEWS0331
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 13 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-07-302, NCT00538239
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: BMT 0499 Solid, NCT00179816
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 10 and over
Sponsor: Other
Protocol IDs: 2005-0889, NCT00492141
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 10 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4021020, NCT00560235
|
|
6.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CHNMC-07053, 07053, CA180 121, NCT00788125
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 4 to 35
Sponsor: NCI
Protocol IDs: NCI-02-C-0259, NCT00047372
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: PSCI-2003-232, NCT00084695
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 40 and under
Sponsor: Other
Protocol IDs: MSKCC-05059, NCT00357396
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: DFCI-04343, 04-343, NCT00357500
|
|
11.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: MSKCC-05122, NCT00445965
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: NCI
Protocol IDs: COG-ADVL0525, ADVL0525, NCT00459147
|
|
13.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: 05-326, NCT00592293
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP13-0707, NCT00668148
|
|
16.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: UMCC 2008.049, NCT00743509
|
|
17.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 25
Sponsor: NCI
Protocol IDs: UIHC-200008086, NCI-V02-1710, NCT00049023, 200008086
|
|
18.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: MSKCC-03133, NCT00089245
|
|
19.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 803776, UPCC 03505, NCT00299962
|
|
20.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI
Protocol IDs: NCI-07-C-0040, NCI-P6981, NCT00428272
|
|
21.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 4 to 16
Sponsor: NCI
Protocol IDs: NCI-07-C-0054, NCT00437047
|
|
22.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 21
Sponsor: NCI
Protocol IDs: NCI-08-C-0007, 08-C-0007, NCI-P6068, 7458, NCT00556881
|
|
23.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 70 and under
Sponsor: NCI
Protocol IDs: UMN-2005LS023, UMN-2005LS023, UMN-MT2004-30, NCT00623077
|
|
24.
|
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 18
Sponsor: NCI
Protocol IDs: JHOC-J0685, NA_00003073, J0685, NCT00499733
|
|
25.
|
Phase: No phase specified
Type: Treatment
Status: Active
Age: 19 months to 35 years
Sponsor: NCI
Protocol IDs: NCI-07-C-0206, 07-C-0206, NCT00526240
|
